{"_canonicalization":{"envelope_id":"axm_ + sha256(envelope minus {signature, axiom_id, anchors})","envelope_signature":"ed25519(envelope minus {signature, axiom_id})","json":"sort_keys=True, separators=(',',':'), ensure_ascii=False, allow_nan=False, utf-8","leaf_hash":"sha256(0x00 || canonical_json(envelope_full))","seal_signature":"ed25519(seal minus {signature, sig_algorithm})"},"axiom_id":"axm_827a14ff916847ab192e85f9a8c0a3c36bd0d445f7e94342975c799afcb6706f","bitcoin_anchor":{"bitcoin_attestations":[],"calendar_attestations":[],"ots_url":"","stamped_at":"","status":"pending_next_stamp"},"envelope":{"anchors":[{"chain":"crovia.axiom_graph","height":0,"merkle_proof":"spider_vendor_press_v1","root_at_anchor":"spider_vendor_press_v1"}],"axiom_id":"axm_827a14ff916847ab192e85f9a8c0a3c36bd0d445f7e94342975c799afcb6706f","axiom_type":"AX.OBS","body":{"axiom_subtype":"news.vendor_press.v1","category":"news","fingerprint":"be1fbb6812180cdceb10b649d4635fdef19b5a9e3606995083f59d20aa0dafde","published":"Mon, 29 Jun 2026 00:00:00 -0400","receipt_hash":"be1fbb6812180cdceb10b649d4635fdef19b5a9e3606995083f59d20aa0dafde","schema":"spider.news.vendor_press.v1","spider":"vendor_press","spider_record":{"axiom_subtype":"news.vendor_press.v1","category":"news","decision_hint":"POSITIVE","envelope_target":"AX.OBS","fingerprint":"be1fbb6812180cdceb10b649d4635fdef19b5a9e3606995083f59d20aa0dafde","observed_at":"2026-06-29T04:44:03.414425Z","parent_run_hash":"36b5ab5c57ae76dc9e1a863501c4d38f172868cfae31b4ba5baf3caffaafb2c4","published":"Mon, 29 Jun 2026 00:00:00 -0400","runtime_version":"0.1.0","schema":"spider.news.vendor_press.v1","source_status":200,"source_url":"https://export.arxiv.org/rss/cs.AI","spider":"vendor_press","summary_excerpt":"arXiv:2606.27824v1 Announce Type: cross \nAbstract: Peptides are a promising therapeutic modality that combine the chemical tunability of small molecules with the target specificity of macromolecular therapeutics. However, designing antigen-specific binding peptides while avoiding toxicity remains a major challenge for therapeutic peptide discovery. Here, we present Pepti-drift, a toxicity-aware latent refinement framework that generates peptide candidates through a single antigen-conditioned drift step. In a peptide embedding space, Pepti-drift learns to attract generated peptide latents toward antigen-matched binding peptides while repelling them from toxicity-associated regions. This is challenging because binding-promoting physicochemical features often overlap with toxicity-associated features in peptide representation space. To address this, we introduce a warm-up strategy to stabilize this competing objective by first learning binding-oriented attraction and then increasing toxic","title":"Pepti-drift: Toxicity-Repulsive Drifting for Antigen-Conditioned Discrete Peptide Generation","url":"https://arxiv.org/abs/2606.27824","vendor":"arxiv_cs_ai"},"summary":"arXiv:2606.27824v1 Announce Type: cross \nAbstract: Peptides are a promising therapeutic modality that combine the chemical tunability of small molecules with the target specificity of macromolecular therapeutics. However, designing antigen-specific binding peptides while avoiding toxicity remains a major challenge for therapeutic peptide discovery. Here, we present Pepti-drift, a toxicity-aware latent refinement framework that generates peptide candidates through a single antigen-conditioned drift step. In a peptide embedding space, Pepti-drift learns to attract generated peptide latents toward antigen-matched binding peptides while repelling them from toxicity-associated regions. This is challenging because binding-promoting physicochemical features often overlap with toxicity-associated features in peptide representation space. To address this, we introduce a warm-up strategy to stabilize this competing objective by first learning binding-oriented attraction and then increasing toxic","title":"Pepti-drift: Toxicity-Repulsive Drifting for Antigen-Conditioned Discrete Peptide Generation","vendor":"arxiv_cs_ai"},"confidence":{"method":"deterministic"},"decision":"POSITIVE","issued_at":"2026-06-29T04:44:03Z","notes":"Spider vendor_press (news) news.vendor_press.v1","object":{"captured_by":"crovia.spider.vendor_press","primary_source_url":"https://arxiv.org/abs/2606.27824"},"predecessors":[],"schema":"crovia.axiom.v1","signature":"ed25519:db5d0d1c882d03be27eef02b76edeb726078bd432f1c71deb41868ee0853ed9d7dd4623fdd4ff0fd83bdcda4ddc06f0ce99a5f1ec946081f4db49a12ccf75202","signer":"crovia.substrate","subject":{"observed_at":"2026-06-29T04:44:03Z","source_collector":"spider:vendor_press","target_id":"https://arxiv.org/abs/2606.27824"},"tsa":{"authority":"crovia.substrate.bootstrap","rfc3161_token":"{\"kind\":\"crovia.bootstrap.tsa\",\"source_jsonl\":\"/opt/crovia/spider/data/news/vendor_press_v1.jsonl\",\"source_seal_merkle_root\":\"spider_vendor_press_v1\",\"upgrade_path\":\"Sessione H \\u2014 OpenTimestamps weekly anchor\"}"},"zk_mode":"clear","zk_proof":null},"ledger":{"leaf_hash":"4a81053e324e15dfe4e8a8dbab0a447365fdd6f29682e70b9c0587604242fd48","leaf_index":261392,"ledger_path":"/opt/crovia/substrate/axiom_ledger.jsonl"},"merkle_proof":{"hash_alg":"sha256","leaf_prefix":"0x00","node_prefix":"0x01","odd_leaf_rule":"duplicate_last","path":[{"sibling":"e3c0c8a22a65970d0ac22e04a0da70cffd296091fa1bab9ac955f68c4f766a79","side":"right"},{"sibling":"def99b4e2d0de15aa900b389663272c26d121faa9122289de23ff34a5d1c8cf4","side":"right"},{"sibling":"147d703d0aadcb5e630d8a42d3c95ea135abb7ec08fe5a84e046d4c23cd07c78","side":"right"},{"sibling":"be72073a27750429bb4e0e933efb20651f46a11f904d4a672ef0f08e7ba34e68","side":"right"},{"sibling":"e67971211d8fb4d42082e567d811e52c51a123210399c1f44052196149b09167","side":"left"},{"sibling":"387418df4d0fbb0c1d5a9c5d2f863bae723a6196cfb15782c9a0d7d4c7874571","side":"right"},{"sibling":"f598b90b37d7f9301fa045df6c69e9936b54d84361d68c339f86d13ecd08335e","side":"right"},{"sibling":"4b4bda5fa1fb23989b8f6f192c36dadc8266c378c69d42945af35c9d6ab81a10","side":"right"},{"sibling":"6d1df65d14253ed3a13c03e25aa9adcd9a091d8062a82e8586bcaee74013b90e","side":"left"},{"sibling":"9f9daa9d12e65b219f34c92aec45450536b79a42b8892050d66961432ae28ed1","side":"right"},{"sibling":"b5725d7b0807dc6da32d9788f20057fa8726be38d30a9ebdabc605ae92739122","side":"left"},{"sibling":"e321b2cac14cbe28f76ccb7938249a40ff60cd5d2128b5634be046ea10e984b8","side":"left"},{"sibling":"5900dc6c7d13855af9d0385baf1691ec386df33e450c422af1cabe0a36e40ad8","side":"left"},{"sibling":"ae636ddee98c71ab7a7dc55ddfab70c7f710a2b6abfdf7a8b5d16a4017d1c0d1","side":"left"},{"sibling":"f29798d8bb6aa9900eab878992d9ff0c53266debd87472f31ab26a6a3fb55880","side":"left"},{"sibling":"a04392fb9f2a3a620840e3b3fecd93d12e6d224e481c162389d8ae64e7194599","side":"left"},{"sibling":"c300cf0154c136afc09b1702a0be98f4ba5b6dc5cf57e8cc714ec1eaf4196eff","side":"left"},{"sibling":"d841ad93efda0869e5eb97678f348f03f5caab4353e05ff4bf18f47fb945b822","side":"left"}]},"schema":"crovia.axiom_proof.v1","seal":{"first_collector_run_id":"","first_receipt_hash":"","jsonl_path":"/opt/crovia/substrate/axiom_ledger.jsonl","key_id":"430895f101d38164","last_collector_run_id":"","last_receipt_hash":"","leaf_count":261662,"merkle_root":"aa8865c239aa2eb6c8aa7c6250f56b3cd5709854a8a07f6a29eb4ddd8802cb6f","public_key_hex":"cf742e26f75669dc673cb5c0786a1ae23ae8ca19c347317192ce40c28a7ff25c","run_id":"hourly_json_retrofit_20260629T053701Z","schema":"crovia.seal.v1","seal_family_version":"crovia-seal-family/1","seal_kind":"substrate_batch","sealed_at":"2026-06-29T05:38:02Z","sig_algorithm":"ed25519","signature":"476329233e82fb35fba2552ddc5d1d75b2bdd8513bbd281e9c40a0b8e475df374a62dcd8b456b0c5e8815984f5b4bf0983ae95d2cf4d7412ebb13a433b933c0a","signer_version":"1.1.0"},"trust_root":{"key_id":"430895f101d38164","public_key_hex":"cf742e26f75669dc673cb5c0786a1ae23ae8ca19c347317192ce40c28a7ff25c","signature_algorithm":"ed25519","url":"/registry/canon/TRUST_ROOT.md"},"verifier":{"spec":"/registry/canon/AXIOM_RECEIPT_v1.md","url":"/v/axm_827a14ff916847ab192e85f9a8c0a3c36bd0d445f7e94342975c799afcb6706f"}}